Pharmacological interventions that increase myofiber size counter the functional decline of
dystrophic muscles,. We show that deacetylase inhibitors increase the size of myofibers in …

Huntington's disease (HD) is an inherited neurodegenerative disorder of which skeletal
muscle atrophy is a common feature, and multiple lines of evidence support a muscle-based …

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease
characterized by a late clinical onset of psychiatric, cognitive, and motor symptoms …

Duchenne muscular dystrophy (DMD) is a fatal muscle disease caused by dystrophin
deficiency. Dystrophin consists of the amino terminus, central rod domain with 24 spectrin …

Parkinson's disease is characterized by the intracellular accumulation of α-synuclein which
has been linked to early dopaminergic axonal degeneration. Identifying druggable targets …

Background In the search of genetic determinants of Duchenne muscular dystrophy (DMD)
severity, LTBP4, a member of the latent TGF-β binding protein family, emerged as an …

BACKGROUND: Skeletal muscle atrophy during aging, a process known as sarcopenia, is
associated with muscle weakness, frailty, and the loss of independence in older adults. The …

Background Transforming growth factor‐β‐activated kinase 1 (TAK1) plays a key role in
regulating fibroblast and myoblast proliferation and differentiation. However, the TAK1 …

Skeletal muscle atrophy promotes muscle weakness, limiting activities of daily living.
However, mechanisms underlying atrophy remain unclear. Here, we show that skeletal …

Histone deacetylase inhibitors (HDACIs) are known to promote skeletal muscle formation.
However, their mechanisms that include effects on the expression of major muscle …